[1. Bayraktutan U, Kantarci M, Pirimoglu B, Ogul H, Okur A, Gursan N. Utility of diffusion-weighted imaging in the diagnosis of inguinal lymph node metastasis with malignant melanoma. World J Clin Cases 2014; 2(2): 42-4.10.12998/wjcc.v2.i2.42393621924579071]Search in Google Scholar
[2. Higgins HW, Lee KC, Leffell DJ. Point of care cutaneous imaging technology in melanoma screening and mole mapping. F1000Prime Rep 2014; 6: 34.10.12703/P6-34401791024860656]Search in Google Scholar
[3. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008; 3(5): 569-85.10.1586/17469872.3.5.569260164119649148]Search in Google Scholar
[4. Jain D, Singh T, Kumar N, Daga MK. Metastatic malignant melanoma in bone marrow with occult primary site - a case report with review of literature. Diagnostic Pathology 2007; 2: 38.10.1186/1746-1596-2-38214005217910749]Search in Google Scholar
[5. Serrier C, Lesesve JF. Metastatic malignant melanoma in the bone marrow. Blood 2013; 121(5): 721.10.1182/blood-2012-09-45454623484212]Search in Google Scholar
[6. Potepan P, Spagnoli I, Danesini GM, Laffranchi A, Gadda D, Mascheroni L, Guzzon A. The radiodiagnosis of bone metastases from melanoma. Radiol Med 1994; 87(6): 741-6.]Search in Google Scholar
[7. Zhang Y, Zhao Ch, Liu H, Hou H, Zhang H. Multiple Metastasis-Like Bone Lesions in Scintigraphic Imaging. J Biomed Biotechnol 2012; 2012: 957364.10.1155/2012/957364331246422505821]Search in Google Scholar
[8. Brenner AI, Koshy J, Morey J, Lin C, DiPoce J. The bone scan. Semin Nucl Med 2012; 42(1): 11-26. 10.1053/j.semnuclmed.2011.07.00522117809]Search in Google Scholar
[9. Ghosh P. The role of SPECT/CT in skeletal malignances. Semin Musculoskelet Radiol 2014; 18(2): 175-93.10.1055/s-0034-137101924715449]Search in Google Scholar
[10. Krzhivitskii PI, Kanaev SV, Novikov SN, Zhukova LA, Ponomarëva OI, Negustorov IuF. SPECT-CT in the diagnosis of metastatic skeletal lesion. Vopr Onkol 2014; 60(1): 56-63.]Search in Google Scholar
[11. Kuwert T. Bone Imaging with SPECT-CT. In: Fanti S, Farsad M, Mansi L et al. Atlas of SPECT/CT. Springer - Verlag Berlin Heidelberg 2011: 105-19.10.1007/978-3-642-15726-4_4]Search in Google Scholar
[12. Tan JC, Chatterton BE. Is there an added clinical value of “true“ whole body (18)F-FDG PET/CT imaging in patients with malignant melanoma? Hell J Nucl Med 2012; 15(3): 202-5.]Search in Google Scholar
[13. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012; 53(8): 1244-52.10.2967/jnumed.112.10930622782313]Search in Google Scholar
[14. Laurent V, Trausch G, Bruot O, Olivier P, Felblinger J, Régent D. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advanteges of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol 2010; 75(3): 376-83.10.1016/j.ejrad.2009.04.059]Search in Google Scholar
[15. Kardamakis D, Vassilious V, Chow E. Bone metastases. A Translational and Clinical Approach. Springer Science + Business Media B.V. 2009: 400.10.1007/978-1-4020-9819-2]Search in Google Scholar
[16. Abdel-Sater KA, Mansour H. Bone biomarkers of ovariectomised rats after leptin therapy. Bratisl Lek Listy 2013; 114(6): 303-7.]Search in Google Scholar
[17. Biver E. Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 2012; 19(6): 468-73.10.1097/MED.0b013e3283591492]Search in Google Scholar
[18. D Oronzo S, Tamma A, Simone V, Longo V, Silvestris F. Bone health in the oncologic patient. Recenti Prog Med 2012; 103(10): 373-83.]Search in Google Scholar
[19. Brountzos E, Panagiotou I, Bafaloukos D, Kelekis D. Bone metastases from malignant melanoma: a retrospective review and analysis of 28 cases. Radiol Oncol 2001; 35(3): 209-14.]Search in Google Scholar
[20. Brown JP, Delmas PD, Malaval L, Edouard G, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet1984; i:1091-4.10.1016/S0140-6736(84)92506-6]Search in Google Scholar
[21. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990; 66(1): 167-72.10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9]Search in Google Scholar
[22. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 1986; 77: 985-91.10.1172/JCI112400]Search in Google Scholar
[23. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J cancer 1996; 73: 1089-95.10.1038/bjc.1996.210]Search in Google Scholar
[24. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 131-8.10.1200/JCO.1997.15.1.131]Search in Google Scholar
[25. Zulauf N, Marzi I, Oremek GM. Prognostic value of bone marker beta-crosslaps in patiens with breast carcinoma. J Mol Biomark Diagn 2014; 5: 193.]Search in Google Scholar